MITOMYCIN Drug Patent Profile

Which patents cover Mitomycin, and when can generic versions of Mitomycin launch?

Mitomycin is a drug marketed by Accord Hlthcare, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hospira, Meitheal, and Rk Pharma. and is included in twelve NDAs.

The generic ingredient in MITOMYCIN is mitomycin. There are seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mitomycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mitomycin

A generic version of MITOMYCIN was approved as mitomycin by HIKMA on April 19^th, 1995.

Summary for MITOMYCIN

US Patents:	0
Applicants:	8
NDAs:	12
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	262
Drug Prices:	Drug price information for MITOMYCIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MITOMYCIN
DailyMed Link:	MITOMYCIN at DailyMed

See drug prices for MITOMYCIN

Recent Clinical Trials for MITOMYCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	PHASE3
National Cancer Institute (NCI)	PHASE3
Second Affiliated Hospital, School of Medicine, Zhejiang University	PHASE1

See all MITOMYCIN clinical trials

Pharmacology for MITOMYCIN

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Medical Subject Heading (MeSH) Categories for MITOMYCIN

Alkylating Agents

Antibiotics, Antineoplastic

Cross-Linking Reagents

Nucleic Acid Synthesis Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for MITOMYCIN

L01DC	Other cytotoxic antibiotics
L01D	CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for MITOMYCIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JELMYTO	Powder for Injection	mitomycin	40 mg/vial	211728	1	2023-12-28

US Patents and Regulatory Information for MITOMYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	MITOMYCIN	mitomycin	INJECTABLE;INJECTION	064144-001	Apr 30, 1998	AP	RX	No	Yes
Hospira	MITOMYCIN	mitomycin	INJECTABLE;INJECTION	064106-001	Nov 29, 1995		DISCN	No	No
Rk Pharma	MITOMYCIN	mitomycin	INJECTABLE;INJECTION	203386-001	Oct 13, 2017	AP	RX	No	No
Fresenius Kabi Usa	MITOMYCIN	mitomycin	INJECTABLE;INJECTION	211269-001	Apr 5, 2024	AP	RX	No	No
Eugia Pharma	MITOMYCIN	mitomycin	INJECTABLE;INJECTION	216732-001	Oct 30, 2023		DISCN	No	No
Gland	MITOMYCIN	mitomycin	INJECTABLE;INJECTION	216648-001	Nov 22, 2022	AP	RX	No	No

Market Dynamics and Financial Trajectory for Mitomycin

Last updated: February 20, 2026

What Are the Key Market Drivers for Mitomycin?

Mitomycin, an alkylating agent derived from Streptomyces caespitosus, primarily treats certain cancers, including bladder, anal, and some gastric cancers. Its market is influenced by several factors:

• Medical Need: Growing prevalence of bladder and gastrointestinal cancers sustains demand.
• Clinical Adoption: Established use in intravesical therapy for bladder cancer maintains its clinical relevance.
• Regulatory Landscape: Approved in multiple jurisdictions; ongoing debates around labeling and indications influence market expansion.
• Competition: Generic versions marginally impact pricing, but limited alternatives preserve market share.
• Manufacturing Concentration: Production limited to a handful of manufacturers affects supply and pricing dynamics.

How Does Current Market Size and Future Outlook Compare?

Parameter	Data
2022 Global Market Value	Approximately $300 million
Expected CAGR (2023-2028)	3.5%
Main Markets	North America, Europe, Asia
Leading Companies	Pfizer, B. Braun, generic manufacturers

Forecasts predict moderate growth driven by expanding cancer treatments and potential new indications. Market reports project reaching nearly $370 million by 2028.

What Are the Revenue Streams and Profitability Dynamics?

Mitomycin's revenue streams include:

• Patented formulations (limited due to generics)
• Generic sales: Comprise 70-80% of volume, lower margins
• Ancillary procedures: For example, urological surgeries using Mitomycin-based protocols

Profit margins vary widely based on manufacturing costs, patent status, and market penetration. As patents expire (noted around 2005 for original formulations), pricing pressure increased. Current gross margins approximate 20-25%, with net margins often below 10% due to regulatory costs and supply chain factors.

How Do Regulatory and Patent Policies Affect Market Trajectory?

Patents typically grant exclusivity for 20 years from filing. Post-expiry, generic manufacturers enter the market, reducing prices. The expiration of primary patents in the mid-2000s has led to increased generic competition. New indications or formulations under patent can temporarily boost revenues.

Regulatory restrictions on manufacturing and distribution impact supply stability, influencing prices. Approval of biosimilars or alternative agents could shift market shares away from Mitomycin.

What Are the Risks and Opportunities in the Market?

Risks:

• Price Erosion: Due to generic competition and healthcare cost pressures.
• Regulatory Changes: Stricter approval processes and pricing controls.
• Supply Chain Disruptions: Limited production sources heighten vulnerability.

Opportunities:

• New Indications: Exploration of additional cancer uses.
• Combination Therapies: Use with immuno-oncology agents.
• Regional Expansion: Particularly in emerging markets with rising cancer burdens.

How Will Financial Metrics Evolve?

Metric	2022	2028 (Projected)
Total Revenue	~$300 million	~$370 million
CAGR	3.5%	3.5%
Gross Margin	20-25%	Stable or slightly declining
R&D Spend on New Indications	Increasing	Potentially rising
Market Share (Major Pharma)	Stable	Slight expansion with new formulations

Closing Summary

Mitomycin maintains a niche position in oncology therapeutics, with steady but modest growth driven by cancer prevalence and incorporation into combination regimens. Market expansion remains constrained by generics and regulatory factors, but clinical innovation could create new revenue streams.

Key Takeaways

• The global Mitomycin market stood near $300 million in 2022, with a 3.5% CAGR forecast through 2028.
• Growth is constrained by patent expiration and competition, but new indications and regional expansion offer upside.
• Profitability depends heavily on manufacturing costs, price pressures, and supply chain stability.
• Regulatory environments shape pricing and market access; ongoing amendments may influence future dynamics.
• Innovation in combination therapies could enhance revenue streams, offsetting generic competition.

FAQs

1. How long do patent protections typically last for Mitomycin formulations?
Patent protections generally last 20 years from filing. Most primary patents expired around 2005, leading to increased generic competition.

2. What are major competitors or alternative drugs to Mitomycin in oncology?
Alternatives include agents like cisplatin, 5-FU, and newer targeted therapies depending on the cancer type.

3. Are there ongoing clinical trials exploring new uses for Mitomycin?
Yes, trials are evaluating Mitomycin in combination with immunotherapy agents for various cancers, potentially expanding its indications.

4. How does regional regulation affect Mitomycin pricing?
Regulatory agencies like the FDA, EMA, and others influence approval, labeling, and pricing, with emerging markets often experiencing lower prices and looser regulation.

5. What supply chain risks could impact Mitomycin availability?
Limited production sources and raw material dependencies pose risks, especially if manufacturing facilities face disruptions or regulatory sanctions.

---

References

[1] MarketWatch. (2022). Mitomycin market size and forecast.
[2] GlobalData. (2022). Oncology therapeutics market trends.
[3] U.S. Food and Drug Administration. (2023). Drug approvals and patent expiry timelines.
[4] IMS Health. (2022). Pharmaceutical industry outlook and generic impacts.